Gilles Freyer
6PUBLICATIONS
43CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer
|May 31, 2024
Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort.Pauline Corbaux, Gilles Freyer, Olivier Glehen
|Mar 05, 2024
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.Gilles Freyer, Anne Floquet, Olivier Tredan
|Feb 16, 2024
Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA.Aurore Carrot, Stéphane Oudard, Olivier Colomban
|Jan 12, 2024
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa
Pageof 1
Frequent Collaborators
3 joint publications
Benoit You
2 joint publications
Olivier Colomban
2 joint publications
Michele Lamuraglia
2 joint publications
Michel Fabbro
2 joint publications
Anne Floquet
2 joint publications
Frédéric Selle
1 joint publications
Lilian van Wagensveld
1 joint publications
Maaike A van der Aa
1 joint publications
Gabe S Sonke
1 joint publications
Roy F P M Kruitwagen
